APO Research
Talk to an analyst

APO RESEARCH · REPORT

Ondansetron Oral Drugs

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Ondansetron Oral Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

27 December 2025190 pages

Choose your research edition.

Industry ResearchOndansetron Oral Drugs Industry Research Report 2026134 pages · $2,950 USDIndustry Growth & TrendsGlobal Ondansetron Oral Drugs Industry Growth and Trends Forecast to 2032119 pages · $3,450 USDMarket StructureGlobal Ondansetron Oral Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032190 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Ondansetron Oral Drugs Market Outlook and Growth Opportunities 2026201 pages · $4,250 USDMarket Analysis & ForecastGlobal Ondansetron Oral Drugs Market Analysis and Forecast 2026-2032204 pages · $4,950 USD

Market perspective

The global Ondansetron Oral Drugs market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Ondansetron Oral Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Ondansetron Oral Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Ondansetron Oral Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Ondansetron Oral Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Ondansetron Oral Drugs include GSK, SJZ No.4 Pharmaceutical, Shanghai Pharmaceuticals, Qilu Pharmaceutical, Ningbo Tianheng Pharmaceutical, Jiangsu Hengrui Pharmaceuticals, Sinopharm, PKU Healthcare and Teva, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Ondansetron Oral Drugs market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Ondansetron Oral Drugs and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Ondansetron Oral Drugs sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Ondansetron Oral Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.

Ondansetron Oral Drugs Segment by Company

GSK

SJZ No.4 Pharmaceutical

Shanghai Pharmaceuticals

Qilu Pharmaceutical

Ningbo Tianheng Pharmaceutical

Jiangsu Hengrui Pharmaceuticals

Sinopharm

PKU Healthcare

Teva

Takeda

Novartis

Mylan

Morningside Pharmaceuticals

Henry Schein

Aurobindo Pharma

Aden Healthcare

Ondansetron Oral Drugs Segment by Type

Capsules

Oral Solution

Oral Soluble Pellicles

Tablets

Other

Ondansetron Oral Drugs Segment by Application

Hospital and Clinic

Pharmacy

Other

Ondansetron Oral Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Ondansetron Oral Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Ondansetron Oral Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Ondansetron Oral Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Ondansetron Oral Drugs market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Ondansetron Oral Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Ondansetron Oral Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Ondansetron Oral Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Ondansetron Oral Drugs Industry Trends Table 2. Ondansetron Oral Drugs Industry Drivers Table 3. Ondansetron Oral Drugs Industry Opportunities and Challenges Table 4. Ondansetron Oral Drugs Industry Restraints Table 5. Global Ondansetron Oral Drugs Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Ondansetron Oral Drugs Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Ondansetron Oral Drugs Sales by Manufacturers (K Units) & (2021-2026) Table 8. Global Ondansetron Oral Drugs Sales Market Share by Manufacturers Table 9. Global Ondansetron Oral Drugs Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global Ondansetron Oral Drugs Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Ondansetron Oral Drugs Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Ondansetron Oral Drugs Manufacturers, Product Type & Application Table 13. Global Ondansetron Oral Drugs Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Ondansetron Oral Drugs by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Capsules Table 17. Major Manufacturers of Oral Solution Table 18. Major Manufacturers of Oral Soluble Pellicles Table 19. Major Manufacturers of Tablets Table 20. Major Manufacturers of Other Table 21. Global Ondansetron Oral Drugs Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 22. Global Ondansetron Oral Drugs Sales by Type (2021-2026) & (K Units) Table 23. Global Ondansetron Oral Drugs Sales by Type (2027-2032) & (K Units) Table 24. Global Ondansetron Oral Drugs Sales Market Share by Type (2021-2026) Table 25. Global Ondansetron Oral Drugs Sales Market Share by Type (2027-2032) Table 26. Global Ondansetron Oral Drugs Revenue by Type 2021 VS 2025 VS 2032 (K Units) Table 27. Global Ondansetron Oral Drugs Revenue by Type (2021-2026) & (K Units) Table 28. Global Ondansetron Oral Drugs Revenue by Type (2027-2032) & (K Units) Table 29. Global Ondansetron Oral Drugs Revenue Market Share by Type (2021-2026) Table 30. Global Ondansetron Oral Drugs Revenue Market Share by Type (2027-2032) Table 31. Major Manufacturers of Hospital and Clinic Table 32. Major Manufacturers of Pharmacy Table 33. Major Manufacturers of Other Table 34. Global Ondansetron Oral Drugs Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 35. Global Ondansetron Oral Drugs Sales by Application (2021-2026) & (K Units) Table 36. Global Ondansetron Oral Drugs Sales by Application (2027-2032) & (K Units) Table 37. Global Ondansetron Oral Drugs Sales Market Share by Application (2021-2026) Table 38. Global Ondansetron Oral Drugs Sales Market Share by Application (2027-2032) Table 39. Global Ondansetron Oral Drugs Revenue by Application 2021 VS 2025 VS 2032 (K Units) Table 40. Global Ondansetron Oral Drugs Revenue by Application (2021-2026) & (K Units) Table 41. Global Ondansetron Oral Drugs Revenue by Application (2027-2032) & (K Units) Table 42. Global Ondansetron Oral Drugs Revenue Market Share by Application (2021-2026) Table 43. Global Ondansetron Oral Drugs Revenue Market Share by Application (2027-2032) Table 44. Global Ondansetron Oral Drugs Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 45. Global Ondansetron Oral Drugs Sales by Region (2021-2026) & (K Units) Table 46. Global Ondansetron Oral Drugs Sales Market Share by Region (2021-2026) Table 47. Global Ondansetron Oral Drugs Sales Forecasted by Region (2027-2032) & (K Units) Table 48. Global Ondansetron Oral Drugs Sales Forecasted Market Share by Region (2027-2032) Table 49. North America Ondansetron Oral Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 50. North America Ondansetron Oral Drugs Sales by Country (2021-2026) & (K Units) Table 51. North America Ondansetron Oral Drugs Sales by Country (2027-2032) & (K Units) Table 52. Europe Ondansetron Oral Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 53. Europe Ondansetron Oral Drugs Sales by Country (2021-2026) & (K Units) Table 54. Europe Ondansetron Oral Drugs Sales by Country (2027-2032) & (K Units) Table 55. Asia Pacific Ondansetron Oral Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 56. Asia Pacific Ondansetron Oral Drugs Sales by Country (2021-2026) & (K Units) Table 57. Asia Pacific Ondansetron Oral Drugs Sales by Country (2027-2032) & (K Units) Table 58. South America, Middle East and Africa Ondansetron Oral Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 59. South America, Middle East and Africa Ondansetron Oral Drugs Sales by Country (2021-2026) & (K Units) Table 60. South America, Middle East and Africa Ondansetron Oral Drugs Sales by Country (2027-2032) & (K Units) Table 61. Global Ondansetron Oral Drugs Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 62. Global Ondansetron Oral Drugs Revenue by Region (2021-2026) & (US$ Million) Table 63. Global Ondansetron Oral Drugs Revenue by Region (2027-2032) & (US$ Million) Table 64. Global Ondansetron Oral Drugs Revenue Market Share by Region (2021-2026) Table 65. Global Ondansetron Oral Drugs Revenue Market Share by Region (2027-2032) Table 66. GSK Company Information Table 67. GSK Business Overview Table 68. GSK Ondansetron Oral Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 69. GSK Ondansetron Oral Drugs Product Portfolio Table 70. GSK Recent Development Table 71. SJZ No.4 Pharmaceutical Company Information Table 72. SJZ No.4 Pharmaceutical Business Overview Table 73. SJZ No.4 Pharmaceutical Ondansetron Oral Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 74. SJZ No.4 Pharmaceutical Ondansetron Oral Drugs Product Portfolio Table 75. SJZ No.4 Pharmaceutical Recent Development Table 76. Shanghai Pharmaceuticals Company Information Table 77. Shanghai Pharmaceuticals Business Overview Table 78. Shanghai Pharmaceuticals Ondansetron Oral Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 79. Shanghai Pharmaceuticals Ondansetron Oral Drugs Product Portfolio Table 80. Shanghai Pharmaceuticals Recent Development Table 81. Qilu Pharmaceutical Company Information Table 82. Qilu Pharmaceutical Business Overview Table 83. Qilu Pharmaceutical Ondansetron Oral Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 84. Qilu Pharmaceutical Ondansetron Oral Drugs Product Portfolio Table 85. Qilu Pharmaceutical Recent Development Table 86. Ningbo Tianheng Pharmaceutical Company Information Table 87. Ningbo Tianheng Pharmaceutical Business Overview Table 88. Ningbo Tianheng Pharmaceutical Ondansetron Oral Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 89. Ningbo Tianheng Pharmaceutical Ondansetron Oral Drugs Product Portfolio Table 90. Ningbo Tianheng Pharmaceutical Recent Development Table 91. Jiangsu Hengrui Pharmaceuticals Company Information Table 92. Jiangsu Hengrui Pharmaceuticals Business Overview Table 93. Jiangsu Hengrui Pharmaceuticals Ondansetron Oral Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 94. Jiangsu Hengrui Pharmaceuticals Ondansetron Oral Drugs Product Portfolio Table 95. Jiangsu Hengrui Pharmaceuticals Recent Development Table 96. Sinopharm Company Information Table 97. Sinopharm Business Overview Table 98. Sinopharm Ondansetron Oral Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 99. Sinopharm Ondansetron Oral Drugs Product Portfolio Table 100. Sinopharm Recent Development Table 101. PKU Healthcare Company Information Table 102. PKU Healthcare Business Overview Table 103. PKU Healthcare Ondansetron Oral Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 104. PKU Healthcare Ondansetron Oral Drugs Product Portfolio Table 105. PKU Healthcare Recent Development Table 106. Teva Company Information Table 107. Teva Business Overview Table 108. Teva Ondansetron Oral Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 109. Teva Ondansetron Oral Drugs Product Portfolio Table 110. Teva Recent Development Table 111. Takeda Company Information Table 112. Takeda Business Overview Table 113. Takeda Ondansetron Oral Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 114. Takeda Ondansetron Oral Drugs Product Portfolio Table 115. Takeda Recent Development Table 116. Novartis Company Information Table 117. Novartis Business Overview Table 118. Novartis Ondansetron Oral Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 119. Novartis Ondansetron Oral Drugs Product Portfolio Table 120. Novartis Recent Development Table 121. Mylan Company Information Table 122. Mylan Business Overview Table 123. Mylan Ondansetron Oral Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 124. Mylan Ondansetron Oral Drugs Product Portfolio Table 125. Mylan Recent Development Table 126. Morningside Pharmaceuticals Company Information Table 127. Morningside Pharmaceuticals Business Overview Table 128. Morningside Pharmaceuticals Ondansetron Oral Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 129. Morningside Pharmaceuticals Ondansetron Oral Drugs Product Portfolio Table 130. Morningside Pharmaceuticals Recent Development Table 131. Henry Schein Company Information Table 132. Henry Schein Business Overview Table 133. Henry Schein Ondansetron Oral Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 134. Henry Schein Ondansetron Oral Drugs Product Portfolio Table 135. Henry Schein Recent Development Table 136. Aurobindo Pharma Company Information Table 137. Aurobindo Pharma Business Overview Table 138. Aurobindo Pharma Ondansetron Oral Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 139. Aurobindo Pharma Ondansetron Oral Drugs Product Portfolio Table 140. Aurobindo Pharma Recent Development Table 141. Aden Healthcare Company Information Table 142. Aden Healthcare Business Overview Table 143. Aden Healthcare Ondansetron Oral Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 144. Aden Healthcare Ondansetron Oral Drugs Product Portfolio Table 145. Aden Healthcare Recent Development Table 146. Key Raw Materials Table 147. Raw Materials Key Suppliers Table 148. Ondansetron Oral Drugs Distributors List Table 149. Ondansetron Oral Drugs Customers List Table 150. Research Programs/Design for This Report Table 151. Authors List of This Report Table 152. Secondary Sources Table 153. Primary Sources List of Figures Figure 1. Ondansetron Oral Drugs Product Image Figure 2. Global Ondansetron Oral Drugs Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Ondansetron Oral Drugs Market Size (2021-2032) & (US$ Million) Figure 4. Global Ondansetron Oral Drugs Sales (2021-2032) & (K Units) Figure 5. Global Ondansetron Oral Drugs Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Ondansetron Oral Drugs Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Capsules Image Figure 9. Oral Solution Image Figure 10. Oral Soluble Pellicles Image Figure 11. Tablets Image Figure 12. Other Image Figure 13. Global Ondansetron Oral Drugs Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 14. Global Ondansetron Oral Drugs Sales Market Share 2021 VS 2025 VS 2032 Figure 15. Global Ondansetron Oral Drugs Sales Market Share by Type (2021-2032) Figure 16. Global Ondansetron Oral Drugs Revenue by Type (2021 VS 2025 VS 2032) & (K Units) Figure 17. Global Ondansetron Oral Drugs Revenue Market Share 2021 VS 2025 VS 2032 Figure 18. Global Ondansetron Oral Drugs Revenue Market Share by Type (2021-2032) Figure 19. Hospital and Clinic Image Figure 20. Pharmacy Image Figure 21. Other Image Figure 22. Global Ondansetron Oral Drugs Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 23. Global Ondansetron Oral Drugs Sales Market Share 2021 VS 2025 VS 2032 Figure 24. Global Ondansetron Oral Drugs Sales Market Share by Application (2021-2032) Figure 25. Global Ondansetron Oral Drugs Revenue by Application (2021 VS 2025 VS 2032) & (K Units) Figure 26. Global Ondansetron Oral Drugs Revenue Market Share 2021 VS 2025 VS 2032 Figure 27. Global Ondansetron Oral Drugs Revenue Market Share by Application (2021-2032) Figure 28. North America Ondansetron Oral Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 29. North America Ondansetron Oral Drugs Sales Market Share by Country (2021-2032) Figure 30. U.S. Ondansetron Oral Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 31. Canada Ondansetron Oral Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 32. Mexico Ondansetron Oral Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 33. Europe Ondansetron Oral Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 34. Europe Ondansetron Oral Drugs Sales Market Share by Country (2021-2032) Figure 35. Germany Ondansetron Oral Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 36. France Ondansetron Oral Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 37. U.K. Ondansetron Oral Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 38. Italy Ondansetron Oral Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 39. Netherlands Ondansetron Oral Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 40. Asia Pacific Ondansetron Oral Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 41. Asia Pacific Ondansetron Oral Drugs Sales Market Share by Country (2021-2032) Figure 42. China Ondansetron Oral Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 43. Japan Ondansetron Oral Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 44. South Korea Ondansetron Oral Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 45. Southeast Asia Ondansetron Oral Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 46. India Ondansetron Oral Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 47. Australia Ondansetron Oral Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 48. South America, Middle East and Africa Ondansetron Oral Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 49. South America, Middle East and Africa Ondansetron Oral Drugs Sales Market Share by Country (2021-2032) Figure 50. Brazil Ondansetron Oral Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 51. South Africa Ondansetron Oral Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 52. Saudi Arabia Ondansetron Oral Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 53. Turkey Ondansetron Oral Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 54. Argentina Ondansetron Oral Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 55. UAE Ondansetron Oral Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 56. Egypt Ondansetron Oral Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 57. Chile Ondansetron Oral Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 58. Global Ondansetron Oral Drugs Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 59. Global Ondansetron Oral Drugs Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 60. North America Ondansetron Oral Drugs Revenue (2021-2032) & (US$ Million) Figure 61. North America Ondansetron Oral Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 62. Europe Ondansetron Oral Drugs Revenue (2021-2032) & (US$ Million) Figure 63. Europe Ondansetron Oral Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 64. Asia-Pacific Ondansetron Oral Drugs Revenue (2021-2032) & (US$ Million) Figure 65. Asia-Pacific Ondansetron Oral Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 66. South America, Middle East and Africa Ondansetron Oral Drugs Revenue (2021-2032) & (US$ Million) Figure 67. South America, Middle East and Africa Ondansetron Oral Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 68. Ondansetron Oral Drugs Value Chain Figure 69. Manufacturing Cost Structure Figure 70. Ondansetron Oral Drugs Production Mode & Process Figure 71. Direct Comparison with Distribution Share Figure 72. Distributors Profiles Figure 73. Years Considered Figure 74. Research Process Figure 75. Key Executives Interviewed

Scope & coverage.

Types
  • Capsules
  • Oral Solution
  • Oral Soluble Pellicles
  • Tablets
  • Other
Applications
  • Hospital and Clinic
  • Pharmacy
  • Other
Companies covered
  • GSK
  • SJZ No.4 Pharmaceutical
  • Shanghai Pharmaceuticals
  • Qilu Pharmaceutical
  • Ningbo Tianheng Pharmaceutical
  • Jiangsu Hengrui Pharmaceuticals
  • Sinopharm
  • PKU Healthcare
  • Teva
  • Takeda
  • Novartis
  • Mylan
  • Morningside Pharmaceuticals
  • Henry Schein
  • Aurobindo Pharma
  • Aden Healthcare

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Ondansetron Oral Drugs Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Ondansetron Oral Drugs Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Ondansetron Oral Drugs Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Ondansetron Oral Drugs Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Ondansetron Oral Drugs Market Dynamics
  1. 2.1 Ondansetron Oral Drugs Industry Trends
  2. 2.2 Ondansetron Oral Drugs Industry Drivers
  3. 2.3 Ondansetron Oral Drugs Industry Opportunities and Challenges
  4. 2.4 Ondansetron Oral Drugs Industry Restraints
3 Ondansetron Oral Drugs Market by Manufacturers
  1. 3.1 Global Ondansetron Oral Drugs Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Ondansetron Oral Drugs Sales by Manufacturers (2021-2026)
  3. 3.3 Global Ondansetron Oral Drugs Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Ondansetron Oral Drugs Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Ondansetron Oral Drugs Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Ondansetron Oral Drugs Manufacturers, Product Type & Application
  7. 3.7 Global Ondansetron Oral Drugs Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Ondansetron Oral Drugs Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Ondansetron Oral Drugs Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Ondansetron Oral Drugs Tier 1, Tier 2, and Tier 3
4 Ondansetron Oral Drugs Market by Type
  1. 4.1 Ondansetron Oral Drugs Type Introduction
  2. 4.1.1 Capsules
  3. 4.1.2 Oral Solution
  4. 4.1.3 Oral Soluble Pellicles
  5. 4.1.4 Tablets
  6. 4.1.5 Other
  7. 4.2 Global Ondansetron Oral Drugs Sales by Type
  8. 4.2.1 Global Ondansetron Oral Drugs Sales by Type (2021 VS 2025 VS 2032)
  9. 4.2.2 Global Ondansetron Oral Drugs Sales by Type (2021-2032)
  10. 4.2.3 Global Ondansetron Oral Drugs Sales Market Share by Type (2021-2032)
  11. 4.3 Global Ondansetron Oral Drugs Revenue by Type
  12. 4.3.1 Global Ondansetron Oral Drugs Revenue by Type (2021 VS 2025 VS 2032)
  13. 4.3.2 Global Ondansetron Oral Drugs Revenue by Type (2021-2032)
  14. 4.3.3 Global Ondansetron Oral Drugs Revenue Market Share by Type (2021-2032)
5 Ondansetron Oral Drugs Market by Application
  1. 5.1 Ondansetron Oral Drugs Application Introduction
  2. 5.1.1 Hospital and Clinic
  3. 5.1.2 Pharmacy
  4. 5.1.3 Other
  5. 5.2 Global Ondansetron Oral Drugs Sales by Application
  6. 5.2.1 Global Ondansetron Oral Drugs Sales by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Ondansetron Oral Drugs Sales by Application (2021-2032)
  8. 5.2.3 Global Ondansetron Oral Drugs Sales Market Share by Application (2021-2032)
  9. 5.3 Global Ondansetron Oral Drugs Revenue by Application
  10. 5.3.1 Global Ondansetron Oral Drugs Revenue by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Ondansetron Oral Drugs Revenue by Application (2021-2032)
  12. 5.3.3 Global Ondansetron Oral Drugs Revenue Market Share by Application (2021-2032)
6 Global Ondansetron Oral Drugs Sales by Region
  1. 6.1 Global Ondansetron Oral Drugs Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Ondansetron Oral Drugs Sales by Region (2021-2032)
  3. 6.2.1 Global Ondansetron Oral Drugs Sales by Region (2021-2026)
  4. 6.2.2 Global Ondansetron Oral Drugs Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Ondansetron Oral Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Ondansetron Oral Drugs Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Ondansetron Oral Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Ondansetron Oral Drugs Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Ondansetron Oral Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Ondansetron Oral Drugs Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Ondansetron Oral Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Ondansetron Oral Drugs Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Ondansetron Oral Drugs Revenue by Region
  1. 7.1 Global Ondansetron Oral Drugs Revenue by Region
  2. 7.1.1 Global Ondansetron Oral Drugs Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Ondansetron Oral Drugs Revenue by Region (2021-2026)
  4. 7.1.3 Global Ondansetron Oral Drugs Revenue by Region (2027-2032)
  5. 7.1.4 Global Ondansetron Oral Drugs Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Ondansetron Oral Drugs Revenue (2021-2032)
  8. 7.2.2 North America Ondansetron Oral Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Ondansetron Oral Drugs Revenue (2021-2032)
  11. 7.3.2 Europe Ondansetron Oral Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Ondansetron Oral Drugs Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Ondansetron Oral Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Ondansetron Oral Drugs Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Ondansetron Oral Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 GSK
  2. 8.1.1 GSK Company Information
  3. 8.1.2 GSK Business Overview
  4. 8.1.3 GSK Ondansetron Oral Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 GSK Ondansetron Oral Drugs Product Portfolio
  6. 8.1.5 GSK Recent Developments
  7. 8.2 SJZ No.4 Pharmaceutical
  8. 8.2.1 SJZ No.4 Pharmaceutical Company Information
  9. 8.2.2 SJZ No.4 Pharmaceutical Business Overview
  10. 8.2.3 SJZ No.4 Pharmaceutical Ondansetron Oral Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 SJZ No.4 Pharmaceutical Ondansetron Oral Drugs Product Portfolio
  12. 8.2.5 SJZ No.4 Pharmaceutical Recent Developments
  13. 8.3 Shanghai Pharmaceuticals
  14. 8.3.1 Shanghai Pharmaceuticals Company Information
  15. 8.3.2 Shanghai Pharmaceuticals Business Overview
  16. 8.3.3 Shanghai Pharmaceuticals Ondansetron Oral Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Shanghai Pharmaceuticals Ondansetron Oral Drugs Product Portfolio
  18. 8.3.5 Shanghai Pharmaceuticals Recent Developments
  19. 8.4 Qilu Pharmaceutical
  20. 8.4.1 Qilu Pharmaceutical Company Information
  21. 8.4.2 Qilu Pharmaceutical Business Overview
  22. 8.4.3 Qilu Pharmaceutical Ondansetron Oral Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Qilu Pharmaceutical Ondansetron Oral Drugs Product Portfolio
  24. 8.4.5 Qilu Pharmaceutical Recent Developments
  25. 8.5 Ningbo Tianheng Pharmaceutical
  26. 8.5.1 Ningbo Tianheng Pharmaceutical Company Information
  27. 8.5.2 Ningbo Tianheng Pharmaceutical Business Overview
  28. 8.5.3 Ningbo Tianheng Pharmaceutical Ondansetron Oral Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Ningbo Tianheng Pharmaceutical Ondansetron Oral Drugs Product Portfolio
  30. 8.5.5 Ningbo Tianheng Pharmaceutical Recent Developments
  31. 8.6 Jiangsu Hengrui Pharmaceuticals
  32. 8.6.1 Jiangsu Hengrui Pharmaceuticals Company Information
  33. 8.6.2 Jiangsu Hengrui Pharmaceuticals Business Overview
  34. 8.6.3 Jiangsu Hengrui Pharmaceuticals Ondansetron Oral Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Jiangsu Hengrui Pharmaceuticals Ondansetron Oral Drugs Product Portfolio
  36. 8.6.5 Jiangsu Hengrui Pharmaceuticals Recent Developments
  37. 8.7 Sinopharm
  38. 8.7.1 Sinopharm Company Information
  39. 8.7.2 Sinopharm Business Overview
  40. 8.7.3 Sinopharm Ondansetron Oral Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Sinopharm Ondansetron Oral Drugs Product Portfolio
  42. 8.7.5 Sinopharm Recent Developments
  43. 8.8 PKU Healthcare
  44. 8.8.1 PKU Healthcare Company Information
  45. 8.8.2 PKU Healthcare Business Overview
  46. 8.8.3 PKU Healthcare Ondansetron Oral Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 PKU Healthcare Ondansetron Oral Drugs Product Portfolio
  48. 8.8.5 PKU Healthcare Recent Developments
  49. 8.9 Teva
  50. 8.9.1 Teva Company Information
  51. 8.9.2 Teva Business Overview
  52. 8.9.3 Teva Ondansetron Oral Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Teva Ondansetron Oral Drugs Product Portfolio
  54. 8.9.5 Teva Recent Developments
  55. 8.10 Takeda
  56. 8.10.1 Takeda Company Information
  57. 8.10.2 Takeda Business Overview
  58. 8.10.3 Takeda Ondansetron Oral Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Takeda Ondansetron Oral Drugs Product Portfolio
  60. 8.10.5 Takeda Recent Developments
  61. 8.11 Novartis
  62. 8.11.1 Novartis Company Information
  63. 8.11.2 Novartis Business Overview
  64. 8.11.3 Novartis Ondansetron Oral Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Novartis Ondansetron Oral Drugs Product Portfolio
  66. 8.11.5 Novartis Recent Developments
  67. 8.12 Mylan
  68. 8.12.1 Mylan Company Information
  69. 8.12.2 Mylan Business Overview
  70. 8.12.3 Mylan Ondansetron Oral Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Mylan Ondansetron Oral Drugs Product Portfolio
  72. 8.12.5 Mylan Recent Developments
  73. 8.13 Morningside Pharmaceuticals
  74. 8.13.1 Morningside Pharmaceuticals Company Information
  75. 8.13.2 Morningside Pharmaceuticals Business Overview
  76. 8.13.3 Morningside Pharmaceuticals Ondansetron Oral Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Morningside Pharmaceuticals Ondansetron Oral Drugs Product Portfolio
  78. 8.13.5 Morningside Pharmaceuticals Recent Developments
  79. 8.14 Henry Schein
  80. 8.14.1 Henry Schein Company Information
  81. 8.14.2 Henry Schein Business Overview
  82. 8.14.3 Henry Schein Ondansetron Oral Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Henry Schein Ondansetron Oral Drugs Product Portfolio
  84. 8.14.5 Henry Schein Recent Developments
  85. 8.15 Aurobindo Pharma
  86. 8.15.1 Aurobindo Pharma Company Information
  87. 8.15.2 Aurobindo Pharma Business Overview
  88. 8.15.3 Aurobindo Pharma Ondansetron Oral Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Aurobindo Pharma Ondansetron Oral Drugs Product Portfolio
  90. 8.15.5 Aurobindo Pharma Recent Developments
  91. 8.16 Aden Healthcare
  92. 8.16.1 Aden Healthcare Company Information
  93. 8.16.2 Aden Healthcare Business Overview
  94. 8.16.3 Aden Healthcare Ondansetron Oral Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  95. 8.16.4 Aden Healthcare Ondansetron Oral Drugs Product Portfolio
  96. 8.16.5 Aden Healthcare Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Ondansetron Oral Drugs Value Chain Analysis
  2. 9.1.1 Ondansetron Oral Drugs Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Ondansetron Oral Drugs Production Mode & Process
  6. 9.2 Ondansetron Oral Drugs Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Ondansetron Oral Drugs Distributors
  9. 9.2.3 Ondansetron Oral Drugs Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst